JP2020512019A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512019A5 JP2020512019A5 JP2020503358A JP2020503358A JP2020512019A5 JP 2020512019 A5 JP2020512019 A5 JP 2020512019A5 JP 2020503358 A JP2020503358 A JP 2020503358A JP 2020503358 A JP2020503358 A JP 2020503358A JP 2020512019 A5 JP2020512019 A5 JP 2020512019A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- gene
- ucart
- seq
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023114120A JP7634045B2 (ja) | 2017-03-31 | 2023-07-12 | ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201770239 | 2017-03-31 | ||
| DKPA201770240 | 2017-03-31 | ||
| DKPA201770240 | 2017-03-31 | ||
| DKPA201770239 | 2017-03-31 | ||
| DKPA201770542 | 2017-06-30 | ||
| DKPA201770542 | 2017-06-30 | ||
| EPPCT/EP2017/076800 | 2017-10-19 | ||
| PCT/EP2017/076800 WO2018073393A2 (en) | 2016-10-19 | 2017-10-19 | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| PCT/EP2018/058367 WO2018178377A1 (en) | 2017-03-31 | 2018-03-30 | Universal anti-cd22 chimeric antigen receptor engineered immune cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023114120A Division JP7634045B2 (ja) | 2017-03-31 | 2023-07-12 | ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020512019A JP2020512019A (ja) | 2020-04-23 |
| JP2020512019A5 true JP2020512019A5 (enExample) | 2021-05-06 |
| JP7314115B2 JP7314115B2 (ja) | 2023-07-25 |
Family
ID=63674321
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503358A Active JP7314115B2 (ja) | 2017-03-31 | 2018-03-30 | ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞 |
| JP2023114120A Active JP7634045B2 (ja) | 2017-03-31 | 2023-07-12 | ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023114120A Active JP7634045B2 (ja) | 2017-03-31 | 2023-07-12 | ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11944643B2 (enExample) |
| EP (3) | EP3592380B1 (enExample) |
| JP (2) | JP7314115B2 (enExample) |
| KR (1) | KR102726269B1 (enExample) |
| CN (1) | CN110869046B (enExample) |
| AU (2) | AU2018246378A1 (enExample) |
| BR (1) | BR112019020203A2 (enExample) |
| CA (1) | CA3058268A1 (enExample) |
| DK (1) | DK3592379T3 (enExample) |
| ES (1) | ES2979232T3 (enExample) |
| IL (1) | IL269538B2 (enExample) |
| MX (1) | MX2019011475A (enExample) |
| PT (1) | PT3592379T (enExample) |
| WO (2) | WO2018178377A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3020330A1 (en) * | 2016-04-07 | 2017-10-12 | Bluebird Bio, Inc. | Chimeric antigen receptor t cell compositions |
| JP7148147B2 (ja) | 2016-10-05 | 2022-10-05 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | ブリオスタチン化合物およびその調製方法 |
| AU2018246378A1 (en) * | 2017-03-31 | 2019-10-17 | Cellectis Sa | New universal chimeric antigen receptor T cells specific for CD22 |
| EP3692063A1 (en) | 2017-10-03 | 2020-08-12 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
| CA3095595A1 (en) * | 2018-03-30 | 2019-10-03 | Eureka Therapeutics, Inc. | Constructs targeting cd22 and uses thereof |
| EP3775238A1 (en) * | 2018-04-05 | 2021-02-17 | Juno Therapeutics, Inc. | Methods of producing cells expressing a recombinant receptor and related compositions |
| WO2020132327A1 (en) | 2018-12-19 | 2020-06-25 | The Trustees Of The University Of Pennsylvania | Use of cd2/5/7 knock-out anti-cd2/5/7 chimeric antigen receptor t cells against t cell lymphomas and leukemias |
| EP3959235B1 (en) * | 2019-04-26 | 2023-07-26 | Allogene Therapeutics, Inc. | Rituximab-resistant chimeric antigen receptors and uses thereof |
| JP2022533412A (ja) * | 2019-05-21 | 2022-07-22 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 免疫療法を強化するためのブリオスタチン化合物 |
| EP4127188A4 (en) | 2020-03-31 | 2024-08-21 | Walking Fish Therapeutics | MODIFIED B CELLS AND METHODS OF USE THEREOF |
| CN113527507A (zh) * | 2020-04-16 | 2021-10-22 | 上海赛比曼生物科技有限公司 | 靶向cd22的嵌合抗原受体及其制法和应用 |
| GB202007842D0 (en) * | 2020-05-26 | 2020-07-08 | Quell Therapeutics Ltd | Polypeptide useful in adoptive cell therapy |
| MX2023001244A (es) * | 2020-07-31 | 2023-05-16 | Cellectis Sa | Celulas t que expresan dos car. |
| CN111944850B (zh) * | 2020-08-28 | 2023-03-31 | 澳门大学 | 表达抗cd22嵌合抗原受体和pd-l1阻断蛋白的细胞的制备方法、表达载体及应用 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| TW202237827A (zh) | 2020-12-03 | 2022-10-01 | 美商世紀治療股份有限公司 | 經基因工程改造之細胞及其用途 |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| US20240239864A1 (en) * | 2021-02-16 | 2024-07-18 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Hla class i-restricted t cell receptors against cd22 |
| KR102829757B1 (ko) * | 2021-11-17 | 2025-07-09 | (주)이노베이션바이오 | 인간화된 cd22에 특이적인 항체 및 이를 이용한 키메라 항원 수용체 |
| US20250059569A1 (en) * | 2021-12-22 | 2025-02-20 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for delivery of therapeutic agents to acceptor cells |
| JP2026502616A (ja) * | 2023-01-19 | 2026-01-23 | ウーハン チャオチー バイオテクノロジー カンパニー リミテッド | Ｃａｒ分子、それを含む細胞若しくはエクソソーム、及びそれらの使用 |
| WO2025049961A1 (en) * | 2023-09-01 | 2025-03-06 | Cargo Therapeutics, Inc. | Anti-cd22 chimeric antigen receptor (car) therapies |
| WO2025212803A2 (en) * | 2024-04-03 | 2025-10-09 | Umoja Biopharma, Inc. | Lentiviral delivery of anti-cd22 chimeric antigen receptors |
| CN119775433B (zh) * | 2024-12-09 | 2025-11-28 | 吉林大学第一医院 | 一种细胞膜表达的il-15融合蛋白及其在细胞治疗中的应用 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| AU2337997A (en) | 1996-03-20 | 1997-10-10 | Arizona Board Of Regents, The | Method of treating cancer using c-26 modified bryostatin |
| ATE420157T1 (de) | 1997-04-24 | 2009-01-15 | Univ Washington | Zielgerichtete genveraenderung mit parvoviralen vektoren |
| EP1233956A4 (en) | 1999-11-30 | 2006-07-05 | Univ Leland Stanford Junior | BRYOSTATIN ANALOGUES, METHODS OF SYNTHESIS AND USES |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| BR0108545A (pt) | 2000-02-24 | 2004-06-29 | Xcyte Therapies Inc | Estimulação e concentração simultâneas das células |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| EP2121001B1 (en) | 2007-02-09 | 2014-12-17 | Blanchette Rockefeller Neurosciences, Institute | Therapeutic effects of bryostatins on ischemia/stroke-induced memory impairment and brain injury |
| WO2008102199A1 (en) | 2007-02-20 | 2008-08-28 | Cellectis | Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof |
| KR101962483B1 (ko) * | 2010-11-17 | 2019-03-29 | 추가이 세이야쿠 가부시키가이샤 | 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자 |
| JP5996630B2 (ja) | 2011-04-05 | 2016-09-21 | セレクティスＣｅｌｌｅｃｔｉｓ | コンパクトｔａｌｅ−ヌクレアーゼを作製する方法及びその使用 |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| IN2014CN02906A (enExample) | 2011-10-20 | 2015-07-03 | Us Health | |
| EP3594245A1 (en) | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013126720A2 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for the assessment of target cancer cell resistance to car engineered t cell killing |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| EP4541818A3 (en) * | 2012-05-25 | 2025-07-23 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| ES2714523T3 (es) | 2012-09-04 | 2019-05-28 | Cellectis | Receptor quimérico de antígenos multicatenario y usos del mismo |
| RU2658485C2 (ru) | 2012-10-24 | 2018-06-21 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы м971 |
| DK3309248T3 (da) | 2013-05-29 | 2021-08-02 | Cellectis | Fremgangsmåde til manipulering af T-celler til immunterapi under anvendelse af et RNA-guidet CAS-nuklease-system |
| EP3071687B1 (en) * | 2013-11-22 | 2019-07-31 | Cellectis | Method of engineering chemotherapy drug resistant t-cells for immunotherapy |
| WO2015092024A2 (en) * | 2013-12-20 | 2015-06-25 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
| AU2015216875B2 (en) | 2014-02-14 | 2021-02-25 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| MX373460B (es) * | 2014-03-11 | 2020-04-07 | Cellectis | Metodo para generar celulas t compatibles para el trasplante alogenico. |
| US9944709B2 (en) * | 2014-03-19 | 2018-04-17 | Cellectis | CD123 specific chimeric antigen receptors for cancer immunotherapy |
| CA2945620C (en) * | 2014-04-14 | 2022-12-06 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| WO2016120218A1 (en) | 2015-01-26 | 2016-08-04 | Cellectis | ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (scCARS) FOR CANCER IMMUNOTHERAPY |
| EP3253866B1 (en) * | 2015-02-06 | 2024-12-04 | Cellectis | Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles |
| US10738116B2 (en) * | 2015-03-19 | 2020-08-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dual specific anti-CD22-anti-CD19 chimeric antigen receptors |
| AU2016243583B2 (en) * | 2015-03-27 | 2022-03-10 | President And Fellows Of Harvard College | Modified T cells and methods of making and using the same |
| KR102796744B1 (ko) | 2015-06-09 | 2025-04-15 | 에디타스 메디신, 인코포레이티드 | 이식의 개선을 위한 crispr/cas-관련 방법 및 조성물 |
| US12241053B2 (en) | 2015-10-09 | 2025-03-04 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| CN105958210B (zh) | 2016-05-06 | 2018-10-30 | 中国科学院国家天文台 | Fast望远镜开孔式反射面单元及其开孔方法 |
| CN105968210B (zh) * | 2016-05-13 | 2019-05-31 | 深圳生创精准医疗科技有限公司 | 靶向cd22的强杀伤性嵌合抗原受体t细胞及其在制备治疗肿瘤的药物中的用途 |
| JP7195154B2 (ja) | 2016-07-06 | 2022-12-23 | セレクティス | 初代免疫細胞における逐次遺伝子編集 |
| WO2018073393A2 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| WO2018073394A1 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Cell death inducing chimeric antigen receptors |
| WO2018073391A1 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Targeted gene insertion for improved immune cells therapy |
| AU2018246378A1 (en) | 2017-03-31 | 2019-10-17 | Cellectis Sa | New universal chimeric antigen receptor T cells specific for CD22 |
| CA3067914A1 (en) * | 2017-06-30 | 2019-01-03 | Cellectis | Cellular immunotherapy for repetitive administration |
| EP4185616A1 (en) * | 2020-07-24 | 2023-05-31 | Cellectis S.A. | T-cells expressing immune cell engagers in allogenic settings |
-
2018
- 2018-03-30 AU AU2018246378A patent/AU2018246378A1/en not_active Abandoned
- 2018-03-30 CA CA3058268A patent/CA3058268A1/en active Pending
- 2018-03-30 AU AU2018246377A patent/AU2018246377B2/en active Active
- 2018-03-30 WO PCT/EP2018/058367 patent/WO2018178377A1/en not_active Ceased
- 2018-03-30 US US16/498,899 patent/US11944643B2/en active Active
- 2018-03-30 EP EP18715025.5A patent/EP3592380B1/en active Active
- 2018-03-30 EP EP18715024.8A patent/EP3592379B1/en active Active
- 2018-03-30 ES ES18715024T patent/ES2979232T3/es active Active
- 2018-03-30 BR BR112019020203-0A patent/BR112019020203A2/pt active Search and Examination
- 2018-03-30 EP EP24166930.8A patent/EP4414380A3/en active Pending
- 2018-03-30 WO PCT/EP2018/058368 patent/WO2018178378A1/en not_active Ceased
- 2018-03-30 KR KR1020197032371A patent/KR102726269B1/ko active Active
- 2018-03-30 JP JP2020503358A patent/JP7314115B2/ja active Active
- 2018-03-30 PT PT187150248T patent/PT3592379T/pt unknown
- 2018-03-30 US US16/498,276 patent/US11690873B2/en active Active
- 2018-03-30 MX MX2019011475A patent/MX2019011475A/es unknown
- 2018-03-30 CN CN201880036267.2A patent/CN110869046B/zh active Active
- 2018-03-30 DK DK18715024.8T patent/DK3592379T3/da active
-
2019
- 2019-09-23 IL IL269538A patent/IL269538B2/en unknown
-
2023
- 2023-07-12 JP JP2023114120A patent/JP7634045B2/ja active Active
- 2023-12-21 US US18/393,322 patent/US12133867B2/en active Active
-
2024
- 2024-09-26 US US18/898,069 patent/US20250026808A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023139070A5 (enExample) | ||
| CN107109421B (zh) | Car表达载体及car表达t细胞 | |
| CN106536563B (zh) | 嵌合抗原受体 | |
| JP2024105296A5 (enExample) | ||
| JP7461620B2 (ja) | 治療用化合物及び方法 | |
| JP2021531004A5 (enExample) | ||
| JP2019511222A5 (enExample) | ||
| CN104853765A (zh) | 肿瘤特异性t细胞受体 | |
| JP2015527070A5 (enExample) | ||
| CN117321087A (zh) | 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质 | |
| JP7012364B2 (ja) | Ｔ細胞受容体の認識機構を用いたがん又は感染症の治療及び診断 | |
| EP4502150A1 (en) | Engineered immune cell with cd7 gene knock-out and use thereof | |
| JP2021501567A (ja) | Ｙ１８２ｔ突然変異を有するｔ細胞−抗原カプラおよびその方法ならびに使用 | |
| JP7747724B2 (ja) | マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 | |
| CN113195535A (zh) | 用于连接表达car的免疫细胞与抗原呈递细胞的双特异性多肽及其用途 | |
| WO2023207390A1 (zh) | 一种ciita基因被敲除的工程化免疫细胞及其用途 | |
| CN114555815A (zh) | T细胞受体及其使用方法 | |
| JP2018518945A (ja) | 可溶性キメラインターロイキン−１０受容体およびその療法使用 | |
| TWI881993B (zh) | Ｔ細胞受體及其使用方法 | |
| KR20220038776A (ko) | T 세포 수용체 및 이의 사용 방법 | |
| WO2023051361A1 (zh) | 工程化免疫细胞及其用途 | |
| WO2018176034A1 (en) | Modulators of notch signaling and methods of use thereof | |
| CN115073584A (zh) | 一种特异性识别prame抗原肽的tcr及其应用 | |
| KR102961312B1 (ko) | CAR를 발현하는 면역세포와 항원제시세포를 맺어주는 이종(allogeneic) 폴리펩타이드 및 이의 용도 | |
| Arenas-Ramirez | Immunotherapy Using a Novel Agonistic Anti-IL-2 Antibody Combined with Epigenetic Modulation Limits Tumor Immune Escape and Controls Tumor Growth |